Latest Breaking News On - Samir taneja - Page 1 : comparemela.com

Published: Apr 19, 2021   BEVERLY HILLS, Calif., April 19, 2021 /PRNewswire/  GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company s proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, reported financial results for the fourth quarter and year ended December 31, 2020. 2020 was a year of robust clinical progress and milestone achievements for GT Biopharma, which allowed us to accomplish a major corporate milestone in listing GT Biopharma on NASDAQ at the beginning of 2021.  The emerging data from our GTB-3550 TriKE™ program in hematological malignancies, MDS and AML, are encouraging in both safety and efficacy profiles.  The ongoing data profile has demonstrated significant differences from all other NK cell therapies and NK engager companies, making TriKE™ a monotherapy, off-the-shelf platform therapeutic.  TriKE™ exerts its therapeu

United statesSamir tanejaJulie seidelCytovance biologicsMichael handelmanPhilip werthmanRajesh shrotriyaGreg berkSusan roushJeffreys millerAnthonyj cataldoDavid castanedaBeverly hillsMichael breenBrucej wendelIovance biotherapeutics